Peter M. Hecht Ph.D.
Net Worth
Last updated:
What is Peter M. Hecht Ph.D. net worth?
The estimated net worth of Dr. Peter M. Hecht Ph.D. is at least $5,538,201 as of 3 Jun 2021. He owns shares worth $4,873,521 as insider and has received compensation worth at least $664,680 in Cyclerion Therapeutics, Inc..
What is the salary of Peter M. Hecht Ph.D.?
Dr. Peter M. Hecht Ph.D. salary is $110,780 per year as Chief Executive Officer, Interim Chief Financial Officer, Principal Accounting Officer & Director in Cyclerion Therapeutics, Inc..
How old is Peter M. Hecht Ph.D.?
Dr. Peter M. Hecht Ph.D. is 61 years old, born in 1964.
What stocks does Peter M. Hecht Ph.D. currently own?
As insider, Dr. Peter M. Hecht Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cyclerion Therapeutics, Inc. (CYCN) | Chief Executive Officer, Interim Chief Financial Officer, Principal Accounting Officer & Director | 2,047,698 | $2.38 | $4,873,521 |
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Peter M. Hecht Ph.D. insider trading
Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics key executives
Cyclerion Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Andreas Busch Ph.D. (62) Chief Scientific Officer
- Dr. Peter M. Hecht Ph.D. (61) Chief Executive Officer, Interim Chief Financial Officer, Principal Accounting Officer & Director